loading page

CD44v6+ hepatocellular carcinoma cells maintain cell stemness through the Met/cjun/Nanog signaling pathway
  • +7
  • Wei Chen,
  • Ronghua Wang,
  • Yuchong Zhao,
  • Yawen Li,
  • Xiju Wang,
  • Wang Peng,
  • Shuya Bai,
  • Mengli Zheng,
  • Man Liu,
  • Bin Cheng
Wei Chen
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

Corresponding Author:[email protected]

Author Profile
Ronghua Wang
University of Pittsburgh School of Medicine
Author Profile
Yuchong Zhao
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
Yawen Li
Affiliated Hospital of Zunyi Medical University
Author Profile
Xiju Wang
The Affiliated Hospital of Guizhou Medical University
Author Profile
Wang Peng
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
Shuya Bai
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
Mengli Zheng
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
Man Liu
Taikang Tongji (Wuhan) Hospital
Author Profile
Bin Cheng
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile

Abstract

Background and Purpose: Cancer stem cells (CSCs) are a type of cancer cell owning the characteristic of self-renew and differentiation.We hypothesize that the stemness properties in CD44v6+ hepatocellular carcinoma cells (HCC) is promoted via the Met/cjun/Nanog signaling pathway, thus, serves as a valuable target for HCC therapy. Experimental Approach: We use lentiviral shMet and selective Met inhibitor PHA665752 to explore the function of Met/cjun/Nanog axi in CD44v6+ cells. The orthotopic liver xenograft tumor model was used to detect self-renewal ability of CD44v6+ cells. Furthermore, a luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were carried out to find the exact binding site of cjun in the Nanog promoter. Key Results: In this study, we demonstrated that CD44v6+ CSCs not only facilitate the properties of cancer stemness, but also represent the high expression of the HGF/MET signal pathway. Inhibiting the activation of Met in CD44v6+ HCC cells in vidvo and in vitro significantly decrease the expression of cjun and Nanog. Furthermore, we found a binding site of cjun in 1700bp before the transcription start site of Nanog. Conclusion and Implications: The stemness properties of CD44v6+ cells is promoted by the Met/cjun/Nanog signaling pathway. And the cjun is binding in 1700bp before the transcription start site of Nanog. KEYWORDS´╝ÜHepatocellular Carcinoma, Cancer Stem Cells, HGF/MET, CD44v6, cjun